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The Many Faces of Negative 
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Abstract
Negative symptoms are relatively frequent across schizophrenia spectrum disor-
ders diagnostic categories and they represent deficits in different domains such as 
emotional, volitional and experiential. Even though negative symptoms have long 
been recognized as a core feature of schizophrenia, their definition has been chang-
ing over time. Different conceptualization classified this category of symptoms as 
primary or secondary, persistent or transient. At the current moment there are five 
agreed upon domains of the concept of negative symptoms, which are separated 
into two dimensions—experience (anhedonia, avolition, asociality) and expression 
(blunted affect, alogia). Multiple mechanistic pathways have been proposed and 
investigated for each dimension and for each domain. The current chapter attempts 
to address recent advances in the literature regarding the concepts, definitions and 
classifications of negative symptoms and their etiological model.
Keywords: anhedonia, avolition, alogia, blunted affect, negative symptoms, 
schizophrenia
1. Introduction
Schizophrenia is a chronic, debilitating disorder that affects approximately 1% 
of the world’s population[1]. The disorder is a significant socioeconomic burden 
because of the early onset of the disease, the low remission rates, and their debilitat-
ing consequences: as the disease’s progression leads to the inability, for a significant 
share of schizophrenic patients, to fulfill their professional, social and household 
roles [2]. Phenomenologically schizophrenia is considered to be a heterogeneous 
syndrome including several dimensions: positive, disorganization, cognitive, 
affective, and negative dimension. These are the most commonly reported by factor 
analytic studies dimensions of schizophrenia [3–5].
Negative symptoms have long been recognized as a core feature of schizophre-
nia, and the current studies report that their severity has a more significant impact 
on real-world functioning and quality of life than other categories of symptoms 
[6–10]. Negative symptoms, by their definition, interfere with the patient’s ability 
to maintain social activities or personal relationships, to work or study, and even 
to live independently and are minimally influenced by antipsychotic medication 
[11–13]. Even though the attention has shifted from the positive to the negative 
symptoms in the last decades, the latter still represent an unmet therapeutical 
target, and very few pharmaceutical agents are labeling indications for negative 
symptoms [14–17].
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Negative symptoms have been commonly described as first symptoms of 
schizophrenia, and very frequently, they appear during the prodromal phase of the 
disorder [18, 19]. The prevalence of negative symptoms is hard to establish, with 
reports from literature ranging between 40% and 90%, these differences result 
from the heterogeneity of the used definitions, constitutive factors, and assess-
ment methods [20]. The European First Episode Schizophrenia Trial reported that 
at least one negative symptom was noted in up to 54.2% of the patients at baseline 
[21]. The Clinical Antipsychotic Trials of Interventions Effectiveness, which is 
one of the most extensive controlled studies for schizophrenia, reported negative 
symptoms in 40% of the patients [22], and the CLAMORS study reported one or 
more negative symptoms were present in 57.6% of patients [23]. What is known is 
that they can occur at any point during the illness, but the long-term course is less 
clear. Some studies report stability of negative domain [24], while others describe 
an unstable course [25]. Many factors could be accountable for this difference, but it 
is widely accepted that improvement in negative symptoms is more common during 
the first years of the disorder, and an exacerbation is frequently seen in chronic 
patients [26].
Across studies, it is generally evidenced that negative symptoms are frequently 
reported in any disease phase. They are associated with poor functional outcomes, 
which is why it is imperative to assess and address these symptoms to improve the 
quality of life for patients with schizophrenia.
2. The concept of negative symptoms in schizophrenia
2.1 Early descriptions
The classification of the symptoms of schizophrenia as being positive or nega-
tive regards the fact that positive symptoms are a surplus to normal experiences, 
for example, hallucinations or delusions, whereas the negative symptoms are 
represented by diminished experiences or expression [27]. The term of negative 
symptoms was borrowed from neurology, and it was coined by John Reynolds in 
1858 and was introduced in psychiatry by the French psychiatrists Gaetan Gatian de 
Clerambault and Henry Ey [28].
The negative symptoms were considered a fundamental feature of the dis-
ease since its first descriptions by Emil Kraepelin and Eugen Bleuler [27]. Emil 
Kraepelin, influenced by the work of Alois Alzheimer, was the one who named the 
disease dementia praecox. He considered that the process underpinning the mani-
festation of the disease was an affective degeneration. In his treatise “Dementia 
praecox and paraphrenia”, he described the flat affect and the motivational deficits, 
which are now called negative symptoms, and he proposed the theory that the 
affective deficit represents the basis for the psychopathological process [27–30].
Eugen Bleuler renamed the disease schizophrenia and emphasized that there 
is a group of disorders under this name. At a descriptive level, he introduces a 
dichotomy between the symptoms of schizophrenia, and he labels the fundamental 
and accessory symptoms. The fundamental symptoms are described as the essence 
of the illness necessary to diagnose loose associations, ambivalence, affective flat-
tening, and avolition. The accessory symptoms are hallucinations and delusions that 
were not necessary to diagnose schizophrenia but were highly visible and often the 
reason for clinical presentation. Unlike his predecessor, he considers that the affect 
as a process is intact in schizophrenia and that the fundamental psychopathological 
process is the splitting between affect and cognition, from which the symptoms of 
the disease arise [27, 28, 30].
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The interest for negative symptoms decreased and shifted towards the positive 
symptoms once Chlorpromazine was developed and introduced in psychiatric 
wards in 1952. The awareness regarding the importance of these symptoms 
reemerged in the last decades because of their negative influence on the patients’ 
real-life function [10, 11, 31].
2.2 Current perspective
The interest for the negative symptoms is constantly growing, although it 
has been about 40 years since Nancy Andreasen and co-workers (1982) resumed 
this research area and highlighted the importance of this category of symptoms. 
Andreasen defined twenty negative symptoms, which were grouped into five 
factors: flat affect, alogia, avolition/apathy, anhedonia/social withdrawal, and 
attention deficit. She proposed that negative and positive symptoms are part of a 
continuum representing the extreme and opposite poles of this continuum. Patients 
presenting mixed symptoms, positive and negative symptoms, were considered 
intermediate patients [28, 32].
Later, Timothy Crow [33] postulated the hypothesis of two types of disease, 
schizophrenia type I and type II. Type I is characterized by positive symptoms 
(hallucinations, delusions), showing a good response to neuroleptic medication, 
without intellectual deficit, and with an increase in D2 receptors. Type II is charac-
terized by negative symptoms (alogia, affective flattening, decreased interest, and 
pleasure), an inadequate response to neuroleptic medication, intellectual deficits, 
and changes in the temporal lobes’ neural structures. According to this author, type 
I could develop negative symptoms and progress to type II, but type II could not 
transform into type I, even though positive symptoms could appear [33].
In 1988 William Carpenter and collaborators brought to attention a new 
perspective on the concept of negative symptoms and made an essential distinc-
tion between idiopathic, primary negative symptoms and secondary negative 
symptoms. Secondary negative symptoms occur as side effects of neuroleptic 
medication (extrapyramidal symptoms, sedation) or secondary to depression, 
social deprivation or substimulation or secondary to positive symptoms (active 
social withdrawal secondary to paranoid ideation, or diminished expression, which 
could be a coping strategy for patients in an acute psychotic episode who are unable 
to process tumultuous hallucinations). At a phenomenological level, primary and 
secondary negative are very similar and yet very hard to distinguish. The diagnosis 
of primary negative symptoms, according to Carpenter, should be only a diagnosis 
of exclusion. The importance of distinguishing these categories of symptoms is that 
secondary negative symptoms may be responsive to specific treatments [34].
As a result of this classification, deficit schizophrenia was introduced to define 
patients with primary and persistent negative symptoms. The dichotomy, deficit/
non-deficit schizophrenia, is based exclusively on the presence or absence of 
primary and stable negative symptoms [34]. The diagnostic criteria for deficit 
schizophrenia are presented in Table 1. Several subsequent studies have compared 
patients with deficit schizophrenia versus non-deficit schizophrenia and found 
overwhelming evidence that the two types are different in that concerns risk fac-
tors, premorbid functioning, disease evolution, neurobiological basis, and response 
to treatment. The clinical picture of deficit schizophrenia shows more significant 
social withdrawal, anergia, more severe cognitive impairments, poorer premorbid 
adjustment than non-deficit schizophrenia, and often summer birth instead of 
non-deficit schizophrenia, which predominates winter birth [35–39]. Although 
the two diagnostic categories have been validated in several studies, the evolution 
over time of negative symptoms does not always allow a clear distinction between 
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primary and secondary symptoms, making the diagnosis very difficult. Moreover, 
first psychotic episode patients represent another diagnostical challenge [40–42].
A different approach, which tried to reduce the heterogeneity of negative 
symptoms, was proposed by the National Institute for Mental Health (USA) in 
The Consensus Statement on Negative Symptoms (2006), which defined the 
constitutive factors of the negative domain: flat affect, alogia, social withdrawal, 
avolition, and anhedonia, essentially the same areas that have been defined by 
Nancy Andreasen (1982) except for the attention deficit. A short definition of each 
symptom, according to this consensus, is presented in Table 2 [45].
As a result of the same consensus, the National Institute for mental Health 
defined the concept of persistent negative symptoms, which is more applicable in 
the clinical setting than the concept of deficit schizophrenia because of its more 
permissive criteria. The criteria for the persistent negative symptoms imply only a 
period of six months, with at least moderate intensity negative symptoms and low 
levels of positive, depressive, and extrapyramidal symptoms. Secondary negative 
symptoms can be included in this category if they are not responsive to a specific 
treatment [45].
In the attempt to describe the nature, the etiology, and find operational cri-
teria for research in the field, other specific terms were defined: predominant, 
prominent, enduring/non-enduring negative symptoms. Unfortunately, there is 
Flat affect A decrease in the expression of emotions and emotional reactivity to events, observed 
spontaneously during speech or after targeted questions (facial expression, intonation, 
and gestures)
Alogia Quantitative reduction of speech and spontaneity (the amount of information 




Interactions and initiatives to have social contacts are diminished due to decreased 
motivation and decreased desire to form or maintain relationships with other people.
Anhedonia Diminished experience of pleasure for a variety of activities or events, over time of 
the activities or events (consumer anhedonia) or for subsequent activities and events 
(anticipatory anhedonia)
Avolition Reducing the initiative and persistence of goal-oriented activities due to diminished 
motivation
Table 2. 
Definition of negative symptoms of schizophrenia [45].
a. The presence of at least two of the following six negative symptoms:
i. Decreased emotional expression (observed behavior);




vi. Diminished social interest;
b. The presence of symptoms described in point (a) for at least 12 months including periods of clinical 
stability;
c. The symptoms described at point (a) are primary symptoms, not secondary to other factors such as 
anxiety, medication side effects, psychotic symptoms, intellectual disability or depression;
d. The patient meets the DSM criteria (3rd edition, or later editions) for schizophrenia.
Table 1. 
Diagnostic criteria for deficit schizophrenia [34, 43, 44].
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no consensus regarding the exact definition of any of these terms as they were only 
used for research purposes [9].
Up to the present point, negative symptoms are considered to represent a 
heterogeneous domain of psychopathology. Recent factor analytic studies have 
provided evidence that the domain of negative symptoms can be grouped into 
two factors: avolition/apathy and diminished expression. The apathy/avoli-
tion subdomain includes avolition, social withdrawal, and anhedonia, and the 
diminished expression includes affective flattening and alogia [46–48]. This 
factorial structure has been confirmed by several studies using different scales 
for the evaluation of negative symptoms: Scale for the Assessment of Negative 
Symptoms (SANS), Positive and Negative Syndrome Scale (PANSS), Negative 
Symptoms Assessment Scale (NSA-16) and more recently developed scales 
Clinical Assessment Interview for Negative Symptoms (CAINS) and Brief 
Negative Symptom Scale (BNSS), which were specially developed to evaluate 
this factorial structure [49, 50]. Several studies have compared the importance 
of these domains regarding clinical features, disease progression, and impact on 
functioning. The domain of diminished expression (DE) turned out to be more 
persistent over time, have a higher prevalence in the early stages of the disease, 
and be associated with a longer duration of the prodromal phase of the disease 
than the  apathy/avolition (AA) [51–53]. The AA domain is associated with poorer 
functioning, with a longer duration of untreated psychosis and non-adherence 
to treatment. These associations were not reported for the DE domain [47, 52, 54]. 
Research up to this point provided evidence that the AA and DE domains rep-
resent different clinical aspects of schizophrenia. Moreover, if these areas have 
different etiologies and should be approached differently from a therapeutic point 
of view are elements in an ongoing investigation, neuroimaging studies currently 
support this hypothesis [8, 55].
To date, no consensus has been reached on how to approach negative symptoms: 
categorical versus dimensional. Numerous studies demonstrated the validity 
of deficit schizophrenia construct or the subtype characterized by primary and 
persistent negative symptoms [51, 52, 54]. However, the dimensional approach is 
supported by several studies that have shown the presence of negative symptoms 
in other disorders than schizophrenia, such as schizoaffective disorder, depres-
sion, Parkinson’s disease, Huntington’s disease, Alzheimer’s disease, temporal lobe 
epilepsy, and even in the general population [8, 55, 56].
3. The neurobiology of negative symptoms in schizophrenia
The heterogeneity in etiology and clinical manifestation of the negative symp-
toms in schizophrenia led to the exploration of several structural abnormalities, 
pathways, and mechanisms which may underlie this complex of symptoms. The 
attempt to reduce these symptoms’ heterogeneity leads to concepts of deficit and 
non-deficit schizophrenia and diminished expression and avolition/apathy domains. 
Different hypotheses have been constructed for these models’ pathophysiological 
mechanisms, but unfortunately without fully satisfying results [8, 9, 55, 56].
3.1 Deficit schizophrenia versus non-deficit schizophrenia
After deficit schizophrenia was described, several studies brought out data 
supporting the hypothesis that deficit schizophrenia differs from non-deficit 
schizophrenia in terms of risk factors, premorbid functioning, the evolution of the 
disease, neurobiological basis, and response to treatment [35–39]. Epidemiological 
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studies support a prevalence of deficit schizophrenia: 15% of patients with a first 
episode of the disease, 25–30% in clinical trials, and 14–17% in population stud-
ies [35, 57, 58]. Structural and functional brain imaging studies have highlighted 
several differences between patients with deficit and non-deficit schizophrenia. 
Abnormalities and asymmetries in the temporal lobe level, cerebrospinal fluid 
accumulations in the left temporal lobe, volume reduction of the right temporal 
lobe have been reported in patients with deficit schizophrenia compared with 
patients with non-deficit schizophrenia and healthy subjects. Both groups of 
patients had a reduced volume of the dorsolateral prefrontal cortex and temporal 
lobes than healthy subjects [59, 60]. Several studies have reported white matter 
abnormalities, especially in the frontoparietal and frontotemporal circuits in 
patients with deficit schizophrenia. These patients present discontinuities in the 
inferior longitudinal fasciculus, arcuate fasciculus, and uncinate fasciculus, and 
it has been suggested that there may be a connection between these structural 
changes and the social and emotional dysfunctions characteristic for deficit schizo-
phrenia [59, 60]. Functional imaging investigations report a decrease in glucose 
metabolism and a decrease in the frontal and parietal lobes’ blood flow in cases of 
deficit schizophrenia versus non-deficit schizophrenia or healthy volunteers [61, 
62]. Studies that used functional MRI to assess the response to the reward reported 
a reduction of dorsal caudate nucleus activity in patients with deficit schizophrenia 
[63, 64].
Regarding the treatment of deficit schizophrenia, respectively of primary 
negative symptoms, the efficacy of several antipsychotics was evaluated: clozapine, 
olanzapine, zotepine, and amisulpride. These therapeutic options are superior 
to placebo therapy and first-generation antipsychotics, but not other classes of 
atypical antipsychotics, data suggesting that they would be effective for secondary 
negative symptoms [65–68]. Recent studies have evaluated the efficacy of add-
on therapies with agents that stimulate NMDA receptors: glycine, D-serine, and 
D-cycloserine, but no significant improvement in symptoms was reported on the 
primary negative ones [15, 38, 69, 70].
3.2 Persistent negative symptoms
Persistent negative symptoms are a looser category than deficit schizophrenia 
as potential causes of secondary negative symptoms are not completely ruled out, 
but it is assumed that the secondary negative symptoms’ clinical expression is mild 
[45]. Also, this category includes all negative symptoms, primary or secondary, that 
do not respond to commonly used treatments, which are apparent during periods 
of clinical stability of the disease and interfere with the patient’s functionality [45]. 
There is great variability in the prevalence of persistent negative symptoms due 
to different definitions used for this category. Prevalence of persistent negative 
symptoms are higher than deficit schizophrenia and were estimated between 35% 
and 60% [21, 71–73].
Structural and functional imaging studies have reported volume reduction of 
the gray matter in the temporal lobes, cortical atrophy of the right superior tem-
poral gyrus, right parahippocampal gyrus, and left orbitofrontal gyrus, and that 
structural abnormality of the white matter in the frontal lobes could be associated 
with persistent negative symptoms [74–77].
Dopaminergic antagonism is the only common mechanism of drugs used to treat 
psychosis. However, subcortical dopamine excess is accompanied by a prefrontal 
dopaminergic function, which encompasses a reduced D1 receptor activation in the 
prefrontal cortex, dopamine hypoactivity in the caudate nucleus, and modifications 
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in D3 receptor activity. These alterations appear to contribute to the pathogenesis 
of negative symptoms. Cariprazine is an atypical antipsychotic that is a partial 
agonist of dopamine receptors D3 and D2, with high selectivity for D3 receptors, 
which have been shown to be effective for predominant negative symptoms [78, 79]. 
Another compound, MIN-101, that has no affinity for dopaminergic receptors and 
acts on sigma-2 and serotonergic receptors 5-HT2A effectively reduces persistent 
negative symptoms [80].
3.3 Negative symptoms domains: avolition/apathy and diminished expression
Factor analysis studies have suggested that negative symptoms include two 
domains: apathy/avolition and diminished expression, which led to building separate 
hypotheses for these domains [45, 47, 52]. In current conceptualizations, the avoli-
tion/apathy domain is defined as deficits in different motivation areas. Two possible 
mechanisms and circuits are considered to be involved: the reward circuit and the 
salience circuit [81]. Functional MRI studies tried to elucidate the substrate of the 
motivational deficit using tasks involving reward anticipation, and it was found that 
there is an association between the activation of the ventral striatum and the apathy/
avolition domain. This relationship has not been confirmed for the diminished 
expression domain. Only a limited number of studies have investigated the correla-
tions between neural structures and the apathy/avolition domain, and the following 
results were reported: a low volume of the frontal lobes, thinning of the anterior 
cingulate cortex and orbitofrontal cortex, and structural abnormalities of connectiv-
ity between the medial orbitofrontal cortex and the anterior rostral cingulate cortex 
[55, 82–85].
Cognitive-behavioral therapy was the first form of alternative therapy targeting 
poor motivation, anhedonia, and irrational cognitions. It promotes the patient’s 
involvement in defining goals and aims and targets, improving functionality and 
recovery of the patients. A positive effect of cognitive-behavioral therapy on 
negative symptoms in combination with antipsychotic medication has been proved, 
and the beneficial effects persist even after stopping therapy. Functional changes, 
highlighted by functional brain imaging studies, at striatal levels underlie this type 
of therapy’s effectiveness [86, 87].
Some studies suggest that dopaminergic agonists: methylphenidate, amphet-
amine, lisdexamfetamine, modafinil, selegiline are involved in relieving negative 
symptoms without worsening the positive symptoms. The exact mechanisms by 
which this class acts are not completely elucidated. Increasing dopamine and nor-
adrenaline at the frontocortical level or the dopamine action at the striatal limbic 
level are possible mechanisms involved in the assumed action of dopaminergic 
agonists on a motivational deficit [17, 55, 88].
The inflammatory hypothesis of schizophrenia suggests that alterations in the 
prenatal immune system are involved in the disease’s etiology. Anti-inflammatory 
agents studied so far are pregnenolone, acetylsalicylic acid, cyclooxygenase-2, 
minocycline, N-acetylcysteine, and omega-3 fatty acids. To date, clinical trials 
have seemed promising, but these studies need to be replicated on a larger scale 
[89–92].
High frequency transcranial magnetic stimulation (≤10 Hz) intensifies metabo-
lism and excitability in the prefrontal cortex. It has been proved to be effective in 
treating negative symptoms when applied in the early stages of schizophrenia. The 
mechanisms of action of this method involve modulation of NDMA receptors and 
striatal dopamine release. This technique has not been proven effective for alogia, 
but only for the other negative symptoms [93, 94].
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Transcranial direct current stimulation has been mainly studied for positive 
symptoms, auditory hallucinations, but an improvement of negative symptoms 
as a subsidiary result, especially motivational deficits, has been reported. The 
modulation of cortical–subcortical networks can explain the benefits for negative 
symptoms [95, 96].
The diminished expression domain’s pathophysiological mechanisms have 
received less attention than those involved in the apathy/avolition domain. It has 
been hypothesized that this domain is correlated with neurocognitive deficits 
and social cognition deficits [97]. In treatment naïve patients, there is an asso-
ciation between expressive deficits and neurological soft signs, which suggests 
the existence of diffuse neurodevelopmental abnormalities. Functional neuro-
imaging studies that investigated impaired emotional processing have shown a 
hypoactivity of different neural networks: the prefrontal, ventrolateral cortex, 
the amygdala, cingulate cortex, and the cuneus [98–100]. Activation of the 
anterior rostral cingulate cortex was negatively correlated with the diminished 
expression domain in the tasks which involve an interaction between reward and 
cognition [101].
Cognitive training, which aims to improve neurocognitive skills and social cog-
nition, has been shown to restore the disrupted neural networks in the prefrontal 
cortex and anterior rostral cingulate cortex [102].
Social skills training for emotion perception, recognition, and expression, 
aims to educate patients about the necessity of social skills, verbal and nonver-
bal communication improvement, and it has been shown that it facilitates the 
release of oxytocin [103]. Considering the hypothesis that the strengthening 
social cognition could have beneficial effects on the diminished expression, the 
administration of intranasal oxytocin was studied, given its action on serotonin 
and dopamine in the nucleus accumbens and amygdala. Oxytocin is effective in 
emotion recognition and the theory of mind as add-on therapy and being used in 
the long term [104].
4. Genetic basis of negative symptoms
The progress in the genetics of schizophrenia in the last years has been notice-
able. Heritability represents a statistical estimate to quantitate the relative genetic 
contribution to a trait relative to its environmental contributors. Heritability is the 
amount or proportion of phenotypic variance of the disease of interest in the popu-
lation that is inherited through genetic factors. The heritability of schizophrenia has 
been established at 81% [105], making the genetic factor the most significant for the 
disease.
According to evidence from previous family and association studies, it has been 
suggested that genetic factors are involved in the development of schizophrenia and 
also in its clinical presentation. Studies that investigated genes potentially involved 
in negative symptoms pathogenesis highlighted that classifying patients with 
schizophrenia into specific subtypes based on predominant symptoms is useful for 
selecting the specific treatment. The findings, and references for these studies are 
summarized on Table 3.
Genetics is rapidly growing, with technological discoveries making it increas-
ingly possible to identify common and rare variants on genomic DNA. Much new 
and confirmatory work remains to be performed to elucidate the role of specific 
genetic variants in negative symptoms development and the distinct ways the genes 
and environment interact to result in schizophrenia susceptibility.
9
The Many Faces of Negative Symptoms in Schizophrenia
DOI: http://dx.doi.org/10.5772/intechopen.98412
5. Conclusions
Conceptual work has highlighted that negative symptoms can be defined as 
primary or secondary, persistent, or transient, and they encompass two distinct 
domains: avolition/apathy and diminished expression. Deficit schizophrenia is 
defined as primary enduring negative symptoms, but more operative for research 
and clinical setting is the concept of persistent negative symptoms. Considering the 
heterogeneity of negative symptoms has brought some progress in research on their 
genetic and neurobiological basis and treatment approaches. Unfortunately, their 
underlying pathophysiology is still unknown, and the treatment remains a critical 
unmet need.
Several hypotheses have been proposed for the pathophysiology of schizo-
phrenia, from which the dopaminergic hypothesis remains the leading one. The 
Author Year Findings Journal
Fanous et al. 2005 Variation in DTNBP1 may predispose subjects to a 
form of schizophrenia with high levels of negative 
symptoms.




2006 Significant association between the CTCTAC 
haplotype and lifetime severity of negative 
symptoms in patients with schizophrenia.




2008 Patients with a Val158 homozygote genotype had a 
higher severity of negative symptoms at the onset 
of the schizophrenia




2009 DTNBP1 gene is associated with a schizophrenia 










2010 Association of prepulse inhibition deficits and 
polymorphisms in the a3 subunits of the CHRNA 
gene cluster. CHRNA3 polymorphisms were also 
associated with negative symptoms
Neuropsychopharmacology 
[111]
Xu et al. 2013 Common genetic variations (ST3GAL1, RNF144, 
CTNNA3 and ZNF385D) are associated with 










2016 NKAIN2 was significantly associated with negative 
symptoms
Schizophrenia bulletin [114]
Gao et al. 2018 Abnormal peripheral gene expression
DNA methylation of MMP9 possible biomarker for 
negative symptom
Frontiers in Genetics [115]
Schneider 
et al.
2019 Negative symptoms are core manifestations of 
psychosis in individuals with 22q11DS that strongly 
impact global functioning.
Schizophrenia Research [116]
Abbreviations: DTNBP1 (dystrobrevin binding protein 1), CHRNA3 (nicotinic acetylcholine receptor), BDNF 
(brain-derived neurotrophic factor), MMP9 (Matrix metalloproteinase-9), NKAIN2 (Sodium/Potassium 
Transporting ATPase Interacting 2), 22q11DS (22q11 deletion syndrome).
Table 3. 
Genes potentially involved in negative symptoms’ pathogenesis.
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dopaminergic hypofunction of the frontal lobe and the mesolimbic structures 
seems to be underlying the negative symptoms. Despite the advances in the field, 
many clinical trials still consider the negative symptoms as a monolithic construct 
which might be the reason for the unsatisfactory results.
Further research directions should concentrate on the two distinct negative 
symptoms dimensions apathy/avolition and diminished expression, and even 
further on each symptom and its pathophysiology. Another interesting approach 
is the transdiagnostic one, which could be helpful in the attempt to disentangle the 
mechanisms underlying this category of symptoms by using information gathered 
from depression or Parkinson’s disease.
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